Trials / Completed
CompletedNCT01923194
Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females
A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 215 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction in Chinese females
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Highly Purified Urofollitropin | for Injection |
| DRUG | Recombinant Human Follitropin Alfa | for Injection |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-07-01
- Completion
- 2015-08-01
- First posted
- 2013-08-15
- Last updated
- 2015-08-21
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01923194. Inclusion in this directory is not an endorsement.